London, UK, 17 April 2008 - Ark Therapeutics Group plc ('Ark' or the 'Company')
today announces that it has received notification that all three of its products
currently marketed to the primary care sector in the UK, Kerraboot(R), Flaminal
(R) and Kerraped(R), have been accepted for inclusion on the new NHS Supply
Chain Advanced Woundcare and Topical Negative Pressure Therapy Contract.
